Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $564.95, for a total transaction of $5,367,025.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,887,819.35. This trade represents a 19.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Price Performance

Shares of UTHR stock opened at $581.74 on Wednesday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a 50-day moving average of $553.65 and a two-hundred day moving average of $504.46. The firm has a market cap of $24.69 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 1.80 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the business earned $6.63 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on UTHR shares. TD Cowen raised their price target on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $619.42.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics presented new data from TETON-1, ADVANCE OUTCOMES, and additional research in pulmonary hypertension and pulmonary fibrosis at ATS 2026, which could support the company’s long-term pipeline outlook. Article link
• Neutral Sentiment: Analysts remain broadly constructive, with several recent price target increases and a consensus “Moderate Buy” rating, suggesting the stock still has support from Wall Street despite recent volatility.
• Negative Sentiment: CEO Martine A. Rothblatt sold 9,500 shares, reducing her stake by 19%, and CFO James Edgemond sold 10,000 shares, cutting his holdings by 34.6%. Insider selling can weigh on sentiment because investors may read it as management taking profits after the stock’s strong run. CEO filing CFO filing
• Negative Sentiment: The company also recently reported weaker-than-expected quarterly results, missing on both earnings and revenue, which may still be pressuring valuation even after the stock’s rebound.

Institutional Trading of United Therapeutics

Institutional investors have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management lifted its position in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $31,000. International Assets Investment Management LLC lifted its position in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.